Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 929,640 shares of the company’s stock after acquiring an additional 23,447 shares during the period. Johnson & Johnson accounts for approximately 0.9% of Zurcher Kantonalbank Zurich Cantonalbank’s portfolio, making the stock its 16th largest holding. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Johnson & Johnson were worth $164,221,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Veracity Capital LLC lifted its position in Johnson & Johnson by 1.2% in the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock valued at $888,000 after purchasing an additional 59 shares during the last quarter. Sandy Cove Advisors LLC lifted its position in Johnson & Johnson by 1.6% in the third quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after purchasing an additional 60 shares during the last quarter. LCM Capital Management Inc lifted its position in Johnson & Johnson by 0.7% in the fourth quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after purchasing an additional 61 shares during the last quarter. Arbor Investment Advisors LLC lifted its position in Johnson & Johnson by 2.3% in the fourth quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after purchasing an additional 61 shares during the last quarter. Finally, Mason & Associates Inc lifted its position in Johnson & Johnson by 4.9% in the third quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after purchasing an additional 62 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.20% of the company’s stock.
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The business had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a return on equity of 35.53% and a net margin of 13.22%. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.67 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 10.67 EPS for the current year.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.88%. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s payout ratio is currently 94.56%.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on JNJ shares. Morgan Stanley boosted their price objective on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 19th. StockNews.com assumed coverage on Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating for the company. Atlantic Securities lowered their price objective on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Finally, UBS Group initiated coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price objective for the company. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $173.00.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- United Parcel Service Delivers A Warning To The Market
- Pulte Homes Is Hosting The Better, More Profitable Open House
- Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
- A Top Is In For McDonald’s Corporation Stock
- Strong Demand Makes Cleveland-Cliffs an Undervalued Mid-Cap
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
